Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis
Stig P. Cramer*, Helle J. Simonsen, Aravinthan Varatharaj, Ian Galea, Jette L. Frederiksen, Henrik B.W. Larsson
Dive into the research topics of 'Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis'. Together they form a unique fingerprint.